The main cause of cardiovascular disease (CVD) is narrowing of blood vessels due to atherosclerosis. In such cases stents are chronically implanted in -arteries to physically expand and scaffold the vessels. Each year, ~90,OOO stents are implanted in Canadians. All these minimally invasive procedures involve the use of a catheter. Currently available catheter tubes advance straight in blood vessels; it remain a challenge to the cardiac catheterization in bifurcated cardiac arteries which are blocked.
This proposed research project is about development of new bone-targeting drug called PTHPEG- BP, this new compound will overcome shortages of current clinical peptide hormone PTH, and show better treatment efficacy and lower price then the latter; several new technologies will be used on research of this PTH, such as micro Positron Emission Tomography (PET/CT), and several of its characteristics will be identified such as structure, bioactivity, and metabolism inside body.
This fellowship will develop next generation Cell Pouch™ technology, through testing novel animal study (anti-cell death agents, insulin-producing mouse stem cells and islet health (metabolic engraftment efficiency) in parallel to a safety and efficacy (Phase I/II) clinical study of the Cell Pouch™ in Type 1 diabetic in which an in vitro measure of islet health will be correlated to in vivo graft function.
1) Generate and lead initiatives in drug discovery especially in the area of target identification/validation.
2) Generate transgenic zebrafish lines for nuclear receptor diseases related to oncology and metabolic diseases
3) Apply and supervise drug discovery on nuclear receptor ligand trap fish lines in the area of metabolic disease / cancer to extend state of the art research that leads to the discovery of new therapies
The overarching objective of this proposal is to develop and validate a new, robust and reproducible 3D culture system that supports the clonal growth of primary sources of normal and malignant human epithelial cells and that is suitable for commercialization by STEMCELL Technologies who will partner in its development. The work will systematically address 3 Specific Aims.
The aim of this project is to improve simultaneous EEG-fMRI techniques through the use of constrained principal component analysis (CPCA). The main problem with combining EEG measures and fMRI measures is that recording EEG in the MR scanner always injects noise into the data. CPCA partitions the variability of the data into systematic and error variance.
This study will be a three-arm, dismantling randomized trial aimed to assess the extent to which recovery after colorectal surgery is influenced by postoperative facilitation of nutrition and mobilization. Adult patients (> 18 years) with colonic or rectal diseases planned for colorectal resection at the Montreal General Hospital will be considered for inclusion. Criteria for exclusion will be: metastatic disease, medical conditions that preclude adequate postoperative feeding and/or mobilization (e.g.
Overall aim of the project: To establish the protocol for oocyte cryopreservation which results in a high success rate of embryo development. We will first use mouse oocytes to test the effects of various compounds supplemented in the cryopreservation medium on subsequent oocyte competence. The mouse has been useful model for elucidating various aspects of oogenesis and reproductive development events including, global oocyte gene expression, intra-oocyte redox state, and critical events during meiotic initiation in the ovary, follicle formation and oocyte growth and maturation.
1) To capture and compare microRNA (MIR) signatures in mouse ovarian follicular fluid and spent media of cumulous cells-oocyte complexes (COCs) isolated from infertility mouse models to identify one or more unique MIR signatures that will distinguish competent oocytes from incompetent oocytes.
Peptide therapeutics are a novel approach to treat bacterial and viral infections, which have major advantages over small molecules. Peptide molecules have been used previously to treat HIV infections, and I have previously shown that peptide molecules targeting Chlamydia can prevent infection in vivo. Project Objectives: 1. To take previously characterized peptides, move them onto an HSA scaffold, and evaluate their expression in a yeast system. 2. To test the HSA scaffold therapeutic peptides in vitro against Chlamydia infection, RSV infection, and influenza infection. 3.